Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG33510

KCTD15 Knockout HT29 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

This CRISPR/Cas9-edited polyclonal knockout cell population is derived from HT29 colorectal adenocarcinoma cells with disruption of KCTD15. KCTD15, a CUL3 adaptor, promotes GLI transcription factor degradation to inhibit Hedgehog signaling and modulates Wnt targets via ??-catenin/TCF interaction. It is relevant to colorectal cancer, development, and obesity. Applications include validation by sequencing and western blot, RT-qPCR for expression analysis, cell viability, colony formation, and wound healing assays. Pathway activity can be assessed using TOP/FOP and Hedgehog luciferase reporters, while co-immunoprecipitation and RNA-seq enable protein interaction and transcriptome studies.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HT29

    Gene Name

    KCTD15

    Gene Identifier

    NCBI Gene ID 79047

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    McCoy's 5A

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

This product is a CRISPR/Cas9-generated polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. The KCTD15 gene has been disrupted across the population, yielding a heterogeneous mixture of cells with diverse loss-of-function alleles. This format avoids clonal artifacts and provides a robust system for studying KCTD15-dependent processes. It is ideal for functional genomics and signaling pathway analysis in a colorectal cancer context.

HT29 cells originate from a primary colorectal adenocarcinoma of a 44-year-old female and exhibit epithelial morphology. They are widely used as a model for intestinal epithelial biology, drug absorption, and colorectal tumorigenesis. These cells harbor APC, p53, and BRAF mutations, leading to constitutive Wnt/??-catenin pathway activation and rapid proliferation, offering a relevant genetic backdrop for investigating KCTD15’s regulatory roles.

KCTD15 functions as a substrate adaptor for the CUL3-based E3 ubiquitin ligase, promoting ubiquitination and degradation of the GLI1 and GLI2 transcription factors to inhibit Hedgehog signaling. Additionally, KCTD15 interacts with ??-catenin and TCF/LEF complexes to modulate Wnt target gene expression. Upstream, KCTD15 is induced by BMP and Wnt signals, and it represses Hedgehog-responsive genes. Downstream targets include MYC and CCND1, linking KCTD15 to cell cycle control. Interactors such as SUFU, ZNF503, and TRIM32 further integrate these pathways.

In HT29 cells, where Wnt signaling is constitutively active due to APC truncations, KCTD15 disruption enables dissection of cross-talk between Hedgehog and Wnt pathways. Loss of KCTD15 de-represses GLI proteins and may alter Wnt target expression, affecting proliferation, differentiation, and tumorigenesis. This model is valuable for colorectal cancer research and for exploring KCTD15’s role in obesity-related metabolic signaling, given its genetic associations with adiposity.

Researchers can validate KCTD15 knockout by Sanger sequencing and western blot, and assess transcript levels via RT-qPCR. Functional assays include MTT, colony formation, and wound healing. Signaling output can be measured by TOP/FOP luciferase reporter for Wnt and dual-luciferase for Hedgehog. Co-immunoprecipitation identifies protein interactions, and RNA-seq enables transcriptomic profiling. For more information or custom inquiries, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)